Fundz

Lumithera, Inc. Announces Completion Of Diopsys, Inc. Acquisition

PRIVATEMar 03, 2022

Acquiring Company

LumiThera

Acquired Company

DIOPSYS INC

PoulsboPine BrookInformation TechnologyHealthcareHealth CareHardwareContent And PublishingMedia And EntertainmentVideoCommerce And ShoppingConsumer Electronics

Description

LumiThera Inc., a commercial stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the completion of its acquisition of Diopsys, Inc., a leader in modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual disorders. Diopsys is now a wholly owned subsidiary of LumiThera.

Who to call at LumiThera, and when

When LumiThera changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day LumiThera raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at LumiThera, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at LumiThera. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

LumiThera

Location

19578 10TH AVE NE, SUITE 200

Poulsbo, Washington, United States

About

LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment LumiThera makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Clark E.
Senior decision-maker at this company
••••••••@••••••••

See Clark E.'s verified email →

Cindy
Likely contact at this company
••••••••@••••••••

See Cindy's verified email →

Duane
Likely contact at this company
••••••••@••••••••

See Duane's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for LumiThera's next move

Learn about Strategic plan

Frequently asked

Who acquired DIOPSYS INC?

DIOPSYS INC was acquired by LumiThera, based in Poulsbo. The deal was reported on March 3, 2022. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. LumiThera is privately held and operates in Information Technology.

When did LumiThera acquire DIOPSYS INC?

LumiThera's acquisition of DIOPSYS INC was reported on March 3, 2022. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does DIOPSYS INC do?

Diopsys, Inc. is a leader in modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual disorders. It is privately held, operating in Hardware, and is based in Pine Brook.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.